Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue

T N A Daniëlle van den Berg; H A van Swieten; J C Vos; V Verweij; A C Wouterse; J Deinum; W J Morshuis; G A Rongen; N P Riksen

doi:10.1016/j.ijcard.2016.04.150

Eplerenone does not limit ischemia-reperfusion injury in human myocardial tissue

Int J Cardiol. 2016 Aug 1:216:110-3. doi: 10.1016/j.ijcard.2016.04.150. Epub 2016 Apr 22.

Authors

T N A Daniëlle van den Berg¹, H A van Swieten², J C Vos³, V Verweij³, A C Wouterse³, J Deinum⁴, W J Morshuis², G A Rongen¹, N P Riksen⁵

Affiliations

¹ Department of Pharmacology and Toxicology, Radboud university medical center, Nijmegen, The Netherlands; Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands.
² Department of Cardiothoracic Surgery, Radboud university medical center, Nijmegen, The Netherlands.
³ Department of Pharmacology and Toxicology, Radboud university medical center, Nijmegen, The Netherlands.
⁴ Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands.
⁵ Department of Internal Medicine, Radboud university medical center, Nijmegen, The Netherlands. Electronic address: [email protected].

PMID: 27149239
DOI: 10.1016/j.ijcard.2016.04.150

No abstract available

Keywords: Cardioprotection; Contractile function; Eplerenone; Human atrial tissue; Ischemia-reperfusion injury; Mineralocorticoid receptor antagonists.

Publication types

Clinical Trial

MeSH terms

Aged
Cardiovascular Diseases / pathology
Cardiovascular Diseases / surgery*
Elective Surgical Procedures
Eplerenone
Female
Heart / drug effects*
Heart Atria
Humans
Male
Middle Aged
Mineralocorticoid Receptor Antagonists / pharmacology*
Models, Biological
Random Allocation
Reperfusion Injury / drug therapy*
Spironolactone / analogs & derivatives*
Spironolactone / pharmacology

Substances

Mineralocorticoid Receptor Antagonists
Spironolactone
Eplerenone